BUY
Their ventilator business has grown in recent years tough they struggled to access Covid patients in hospitals. They had great revenues in their last quarter. They're expanding operations as they enter new markets. EBITDA was lower than expected, so shares pulled back. They trade at half the PE of their peers. The CEO is one of the biggest shareholders. (Analysts’ price target is $15.86)
0

Unlock the latest expert's opinion. Its free

Create a FREE account to see the latest opinions & get alerts about when to buy, sell or hold stocks

Unlock the latest opinion & get signals
TOP PICK
In-home, non-invasive respiratory devices. Grows organically and by acquisition. Earnings beat for second consecutive quarter. Awesome management. Growing phenomenally, projected 25% topline growth over next year. Profitable, big cash balance, buying back stock. Discount to peers. NASDAQ listing should generate interest. (Analysts’ price target is $15.01)
0
PAST TOP PICK
(A Top Pick Apr 27/20, Up 16%) Covid has indirectly increased their business. Growing organically and via acquisitions. Reasonable multiple. Either multiple expansion or a takeover target.
0
BUY
There is a lot of growth in this name. They had a bit of a windfall selling equipment during COVID. There is a lot of positive news coming out about their in-home care. There are a lot of positive drivers in this business.
0
TOP PICK
Enjoys strong tailwinds from aging demographics though Covid made it difficult to access older patients. They continue to be acquisitive. Good valuation. They release earnings shortly and this could move the stock higher. He recently bought this. (Analysts’ price target is $16.02)
0
DON'T BUY

He didn't like it for a while, but now more than before. The telehealth space is getting crowded and they've had issues with CMS code. It's a good American company, though doesn't receive much attention here. VMS is merely okay. He prefers other names like Knight Therapeutics. It's a decent, second-tier company.

0
HOLD
He got stopped out of it a while ago. VMD relies on Medicare for a lot of revenues. Clients use sleep-aid systems that are put through Medicare. This revenue stream is coming up for review by Medicare , so this is a risk. Otherwise, VMD checks a lot of boxes. Hold.
0
BUY
They provide home equipment and therapy to deal with sleep apnea and other respiratory issues. Earnings are expected to grow 75%. 2021 ROE 37% as earnings rocket up, expected to jump 85% in 2020 and 16% in 2021. PE is 18x 2020, and 22x in 2021. Positive free cash flow which should double. It could join a U.S. index which will boost the stock. $15.25 price target or 9% upside.
0
TOP PICK
They provide non-invasive ventilators. Medicare is no longer going through a competitive bidding process. (Analysts’ price target is $13.07)
0
COMMENT
It broke above $3.20 and so far it looks okay, but this trades at low volumes.
0
PAST TOP PICK
(A Top Pick Sep 24/18, Up 44%) He got stopped out, a mistake. Very profitable, no debt. But they had concentration risk--they need to diversify their customer base. He might buy them back.
0
TOP PICK
They are in the non-evasive respiratory product market for COPD. Their recent earnings showed 45% increase in revenues. Trades at 20 times earnings, but he thinks they can continue to grow into that. Yield 0%. (Analysts’ price target is $12.50)
0
WAIT
They make breathing masks for sleep apnea patients. Earnings are forecast to $0.35 per share growing to $0.60 next year. A reasonable multiple then.
0
BUY
Have enjoyed 25% margins. They faced speculation of increasing competition, which pressured the stock, so VMD replied that that competition lies years ahead and won't affect them. This trades at a decent 12x next year's earnings. Once VMD lists in the US, their stock price will jump up.
0
WEAK BUY
Small company. Market cap around $250 mill. Not very followed. Decent growth on the revenue side of around 40%. Still have to spend that money. The regulatory issues are big. Very competitive space. But they are very good at it.
0
Showing 1 to 15 of 20 entries

Viemed Healthcare(VMD-T) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for Viemed Healthcare is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Viemed Healthcare(VMD-T) Frequently Asked Questions

What is Viemed Healthcare stock symbol?

Viemed Healthcare is a Canadian stock, trading under the symbol VMD-T on the Toronto Stock Exchange (VMD-CT). It is usually referred to as TSX:VMD or VMD-T

Is Viemed Healthcare a buy or a sell?

In the last year, 1 stock analyst published opinions about VMD-T. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Viemed Healthcare.

Is Viemed Healthcare a good investment or a top pick?

Viemed Healthcare was recommended as a Top Pick by on . Read the latest stock experts ratings for Viemed Healthcare.

Why is Viemed Healthcare stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Viemed Healthcare worth watching?

1 stock analyst on Stockchase covered Viemed Healthcare In the last year. It is a trending stock that is worth watching.

What is Viemed Healthcare stock price?

On 2022-12-06, Viemed Healthcare (VMD-T) stock closed at a price of $9.67.